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La Jolla, California 92037 Nur77 (TR3 or NGFI-B), an orphan member of the
steroid/thyroid/retinoid nuclear receptor superfamily
(Kastner et al., 1995; Mangelsdorf and Evans, 1995;
Zhang, 2002), plays roles in regulating growth and apo-Summary
ptosis (Winoto and Littman, 2002; Zamzami and
Kroemer, 2001; Zhang, 2002). Nur77 expression is rap-The Bcl-2 family proteins are key regulators of apopto-
sis in human diseases and cancers. Though known to idly induced during apoptosis in immature thymocytes
and T cell hybridomas (Liu et al., 1994; Woronicz et al.,block apoptosis, Bcl-2 promotes cell death through
an undefined mechanism. Here, we show that Bcl-2 1994), and cancer cells of lung (Li et al., 1998; Kolluri et
al., 2003), prostate (Li et al., 2000; Uemura and Chang,interacts with orphan nuclear receptor Nur77 (also
known as TR3), which is required for cancer cell apo- 1998), ovary (Holmes et al., 2002, 2003), colon (Wilson
et al., 2003), and stomach (Liu et al., 2002; Wu et al.,ptosis induced by many antineoplastic agents. The
interaction is mediated by the N-terminal loop region 2002). High levels of Nor1, a Nur77-family member, are
associated with favorable responses to several chemo-of Bcl-2 and is required for Nur77 mitochondrial local-
ization and apoptosis. Nur77 binding induces a Bcl-2 therapeutic agents in patients with diffuse large B-cell
lymphoma (Shipp et al., 2002).conformational change that exposes its BH3 domain,
resulting in conversion of Bcl-2 from a protector to a Recently, we discovered a paradigm in cellular apo-
ptosis (Li et al., 2000), wherein Nur77 translocates fromkiller. These findings establish the coupling of Nur77
nuclear receptor with the Bcl-2 apoptotic machinery the nucleus to the cytoplasm, targeting to mitochondria
and inducing cyt c release. Nur77 mitochondrial-tar-and demonstrate that Bcl-2 can manifest opposing
phenotypes, induced by interactions with proteins geting occurs during apoptosis of different types of can-
cer cells (Holmes et al., 2003; Kolluri et al., 2003; Liu etsuch as Nur77, suggesting novel strategies for regulat-
ing apoptosis in cancer and other diseases. al., 2002; Wilson et al., 2003; Wu et al., 2002). Sindbis
virus-induced apoptosis also involves Nur77 transloca-
tion to mitochondria (Lee et al., 2002). How Nur77 targetsIntroduction
mitochondria and induces apoptosis however has
been unclear.Bcl-2-family proteins are evolutionarily conserved regu-
lators of apoptosis (Adams and Cory, 1998; Gross et al., In this study, we investigated the mechanism by which
Nur77 targets mitochondria and induces apoptosis. Our1999; Reed, 1998; Vander Heiden and Thompson, 1999).
All members possess at least one of the four conserved results demonstrate that Nur77 interacts with Bcl-2
through its ligand binding domain (LBD) and that themotifs called Bcl-2 homology (BH) domains. Antiapo-
ptotic members, such as Bcl-2 and Bcl-XL, contain all interaction is required for Nur77 mitochondrial targeting
and Nur77-dependent apoptosis. Interestingly, Nur77four BH domains. Some proapoptotic members, such
as Bax and Bak, contain BH1, BH2, and BH3 domains, binds to the Bcl-2 N-terminal loop region, located be-
while others, such as Bad and Bid, share sequence tween its BH4 and BH3 domains, resulting in a confor-
homology only at the BH3 domain. The Bcl-2 family mational change in Bcl-2, which converts it from a pro-
proteins primarily act at mitochondria to regulate apo- tector to a killer protein.
ptosis, possibly by forming channels in mitochondrial
membranes (Green and Reed, 1998).
One curious and as yet unexplained aspect of some Results
Bcl-2-family proteins is that their phenotypes can be
reversed in some cellular contexts. Overexpression of Nur77 Interacts with Bcl-2
Bcl-2 or Bcl-XL in some cells promotes rather than pre- We investigated whether Nur77 targets to mitochondria
vents apoptosis, whereas Bax and Bak prevent apopto- by binding Bcl-2. In vitro protein binding assays showed
sis under some circumstances (Chen et al., 1996; Fann- that similar proportions of 35S-labeled Bcl-2 or RXR, a
jiang et al., 2003; Grandgirard et al., 1998; Lewis et al., known Nur77 heterodimerization partner, were selec-
1999; Subramanian and Chinnadurai, 2003; Uhlmann et tively pulled-down by GST-Nur77 but not by GST (Figure
al., 1998). Drosophila Bcl-2 homologs exhibit either pro- 1A). Conversely, 35S-labeled Nur77 and Bax, a known
or antiapoptotic activity (Colussi et al., 2000; Igaki et al., heterodimerization partner of Bcl-2, bound equally to
GST-Bcl-2 but not to GST (Figure 1A). In mammalian
two-hybrid studies, Bcl-2/TM, a Bcl-2 mutant lacking*Correspondence: xzhang@burnham.org (X.-k.Z.), jreed@burnham.
org (J.C.R.) its C-terminal transmembrane domain, strongly inter-
Figure 1. Interaction of Nur77 with Bcl-2
(A) GST-pull down. GST-Nur77, GST-Bcl-2, or GST control protein immobilized on glutathione-Sepharose was incubated with in vitro synthesized
35S-labeled Bcl-2, RXR, Nur77, or Bax as indicated. Bound proteins were analyzed by SDS-PAGE autoradiography. Input represents 5% of
protein used in the pull down assays
(B) Mammalian two-hybrid assay. Gal4 reporter gene (Gal4)2-tk-Luc) was transfected into CV-1 cells with the Bcl-2/TM (TM was deleted to
prevent Bcl-2 membrane association) or RXR fused with the Gal-DBD alone or with the Nur77 or Nur77/DBD fused with the Gal-transactivation
domain (TAD). Reporter gene activity was determined 48 hr later.
(C) Inhibition of Nur77-dependent transactivation by Bcl-2. CV-1 cells were transfected with the NurRE-tk-CAT reporter (Li et al., 2000) with
or without Nur77 expression vector together with or without the Bcl-2 or Bax. CAT activity was then determined. The bars in (B) and (C) are
means  SD from three and six experiments, respectively.
(D) Colocalization of endogenous Nur77 and transfected Bcl-2. LNCaP cells were transfected with Bcl-2, treated with or without TPA (100 ng/
ml) for 3 hr, then immunostained with polyclonal rabbit anti-Bcl-2, mouse monoclonal anti-Nur77, or anti-Hsp60 antibody. Nur77, Bcl-2, and
Hsp60 were visualized using confocal microscopy and images were overlaid (overlay). Approximately 80% of TPA-treated cells demon-
strated colocalization.
(E) Colocalization of transfected GFP-Nur77/DBD and Bcl-2. GFP–Nur77/DBD (3 g) and Bcl-2 (1 g) were cotransfected into LNCaP cells.
After 20 hr, cells were immunostained with anti-Bcl-2 antibody. GFP–fusion and Bcl-2 were visualized as in (D). For control, distribution of
transfected GFP empty vector is shown. Approximately 30% of transfected cells exhibited colocalization shown.
(F) In vivo Co-IP assay in LNCaP cells. Lysates from LNCaP cells treated with or without TPA for 3 hr were incubated with mouse monoclonal
anti-Nur77 antibody (Abgent, San Diego, CA). For immunoblotting of immunoprecipitates, anti-Bcl-2 or rabbit polyclonal anti-Nur77 antibody
(Active Motif, Carlsbad, CA) were used.
(G) In vivo Co-IP in H460 cells. Lysates from H460 cells treated with or without 3-Cl-AHPC (106 M) for 3 hr were incubated with anti-Bcl-2
antibody. Immunoblotting of immunoprecipitates was conducted as in (F).
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Figure 2. Ligand binding Domain of Nur77 Interacts with Bcl-2
(A) Schematic representation of Nur77 mutants. The Nur77 DBD and LBD are indicated.
(B-C) In vivo Co-IP of Nur77 mutants and Bcl-2. The indicated Nur77 mutant fused with GFP or the empty GFP vector (6 g) was cotransfected
with the empty vector (pRC/CMV) or Bcl-2 expression vector (2 g) into HEK293T cells. Lysates were immunoprecipitated by using either
polyclonal rabbit anti-Bcl-2 antibody (against whole Bcl-2 protein) or control IgG. Cell lysates and immunoprecipitates were examined by
immunoblotting using anti-GFP antibody. The same membranes were also blotted with anti-Bcl-2 antibody to determine IP specificity and
efficiency. Input represents 5% of cell lysates used in the Co-IP assays.
acted with Nur77 or Nur77/DBD, a Nur77 mutant lack- ure 2A) as GFP fusions. When GFP-Nur77/DBD and
Bcl-2 were cotransfected into HEK293T cells, a signifi-ing its DNA binding domain (DBD), comparable to the
interaction of Nur77 with RXR (Figure 1B). Bcl-2 but cant amount of GFP-Nur77/DBD was coprecipitated
with Bcl-2 by anti-Bcl-2 antibody but not by controlnot Bax potently inhibited Nur77 transactivation (Figure
1C), again suggesting an interaction between Nur77 and IgG (Figure 2B). This Co-IP was specific because Bcl-2
coexpression was required and the GFP control proteinBcl-2.
We next determined whether endogenous Nur77 and did not interact with Bcl-2. Analysis of other Nur77 mu-
tants revealed that the C-terminal domain (DC3), buttransfected Bcl-2 colocalized in cells. The phorbol ester
12-0-tetradecanoyl phorbol-13-acetate (TPA) induces not the N-terminal domain (N168), of Nur77/DBD was
responsible for binding Bcl-2. The C-terminal fragmentthe expression of endogenous Nur77 and its mitochon-
drial localization in LNCaP prostate cancer cells (Li et DC1 (467–536 aa) strongly interacted with Bcl-2, while its
deletion from Nur77/DBD (Nur77/DBD/DC1) largelyal., 2000). In TPA-stimulated cells, the distribution pat-
terns of TPA-induced endogenous Nur77 and trans- abolished the interaction. Furthermore, deletion of a pu-
tative amphipathic -helix (471–488 aa) from Nur77/fected Bcl-2 overlapped extensively in the cytoplasm
and colocalized with Hsp60, a mitochondria-specific DBD (Nur77/DBD/471–488) or mutation of Leu487
in the region to Ala (Nur77/DBD/L487A) significantlyprotein (Figure 1D). Transfected Nur77/DBD and Bcl-2
also colocalized in cells. The green fluorescent protein impaired the interaction between Nur77/DBD and
Bcl-2 (Figure 2C). Thus, the DC1 region in the Nur77(GFP) tagged Nur77/DBD, which constitutively resides
on mitochondria in LNCaP cells (Li et al., 2000), dis- LBD is crucial for Bcl-2 interaction.
played a distribution pattern that overlapped extensively
with coexpressed Bcl-2, while control GFP protein dis- The Bcl-2 Loop Region, but Not Its Hydrophobic
Groove, Is Responsible for Nur77 Bindingtributed diffusely in cells (Figure 1E).
The interaction between Nur77 and Bcl-2 was further Bcl-2 and Bcl-XL have hydrophobic crevices on their
surfaces that bind the BH3 domains of other family mem-confirmed by coimmunoprecipitation (Co-IP) assays. As
shown in Figure 1F, Bcl-2 was specifically coimmuno- bers (Sattler et al., 1997). To examine whether Nur77
binds to the Bcl-2 hydrophobic groove, we analyzed theprecipitated by anti-Nur77 antibody in TPA-treated cells
but not in nontreated cells. Co-IP using lysates from interaction of Nur77/DBD with several deletion or point
mutants of Bcl-2 (Figure 3A), which are defective in form-H460 lung cancer cells treated with AHPN analog 3-Cl-
AHPC, which potently induces Nur77 expression, mito- ing the hydrophobic groove (Petros et al., 2001; Sattler
et al., 1997). Deletion (data not shown) or point mutationschondrial targeting and apoptosis (Kolluri et al., 2003),
also demonstrated a strong interaction between endog- (Y108K, L137A, G145A, or R146Q) in Bcl-2 abolished or
reduced the interaction with Bax (Figure 3B). In contrast,enous Nur77 and Bcl-2 (Figure 1G).
these mutants retained the ability to bind Nur77/DBD
(Figure 3C). We also analyzed whether Bax or Bcl-Gs,The Nur77 LBD Is Required for Binding Bcl-2
To identify the Nur77 domain responsible for interaction a BH3-only Bcl-2-family protein (Guo et al., 2001), could
compete with Nur77 for binding Bcl-2. Our resultswith Bcl-2, we constructed several Nur77 mutants (Fig-
Cell
530
Figure 3. The Bcl-2 Loop Region Interacts with Nur77
(A) Schematic representation of Bcl-2 and its mutants. BH and loop domains and -helical regions are indicated.
(B) Mutations in the Bcl-2 hydrophobic groove abolish Bcl-2 interaction with Bax.
(C) The Bcl-2 hydrophobic groove is not required for Bcl-2 binding to Nur77/DBD. Co-IP assays (B and C) were performed as in Figure 2B
using lysates from HEK293T cells transfected with GFP-Nur77/DBD and the empty vector or the indicated Bcl-2 plasmid. Immunoprecipitates
and lysates were examined by immunoblotting using the indicated antibodies.
(D) BH3-only protein Bcl-Gs does not compete with DC1 for binding to Bcl-2. GFP-DC1 (4 g) was expressed in HEK293T cells with or without
Bcl-2 (2 g) in the presence or absence of GFP-Bcl-Gs or GFP-Bcl-Gs/L216E (4 g). Lysates were immunoprecipitated by anti-Bcl-2 antibody,
followed by immunoblotting with anti-GFP or anti-Bcl-2 antibody.
(E) Bax does not compete with Nur77/DBD for binding to Bcl-2. GFP-Nur77/DBD (6 g) was expressed in HEK293T cells with or without
Bcl-2 (2 g) in the presence or absence of Bax (2 g). Lysates were immunoprecipitated by anti-Bcl-2 antibody. Immunoprecipitates and
lysates were examined by immunoblotting using anti-GFP, anti-Bcl-2, or anti-HA antibody.
(F) The Bcl-2 N-terminal loop region is essential for Nur77/Bcl-2 interaction. GFP-Nur77/DBD was cotransfected with the indicated Bcl-2
mutant plasmid into HEK293T cells. Lysates were immunoprecipitated by anti-myc or Bcl-2 antibody as indicated. Immunoprecipitates were
analyzed by immunoblotting with anti-GFP, anti-Bcl-2, or anti-myc antibody.
showed that neither Bcl-Gs (Figure 3D) nor Bax (Figure Indeed, the first 80 amino acid residues of Bcl-2 (Bcl-2/
1-80), like the full-length Bcl-2, strongly interacted with3E) interfered with DC1 or Nur77/DBD binding to Bcl-2.
Rather, these proteins consistently enhanced their inter- Nur77/DBD (Figure 3F). The Bcl-2/1-80 encompasses
the BH4 domain and an unstructured loop domain. Toaction with Bcl-2. Thus, binding of Bcl-2 to Nur77 is
distinct for its binding to Bcl-Gs and Bax and does not determine whether the BH4 domain or the loop region
was responsible for binding to Nur77/DBD, we investi-require the BH3 binding hydrophobic groove in Bcl-2.
The above observations suggested that the N-ter- gated Nur77/DBD interaction with Bcl-2 mutants lack-
ing the BH4 domain (Bcl-2/BH4) or the loop regionminal portion of Bcl-2 was responsible for binding Nur77.
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(Bcl-2/Loop) (Figure 3F). Co-IP assays demonstrated Bcl-2 for binding to Nur77. Together, these results dem-
onstrate that Bcl-2 acts as a receptor for Nur77 and isthat the Bcl-2/BH4 retained the ability to interact with
responsible for Nur77 mitochondrial targeting.Nur77/DBD, whereas Bcl-2/Loop did not (Figure 3F).
Thus, the loop region of Bcl-2 is required for binding
Nur77 Interaction with Bcl-2 Triggers cyt cto Nur77.
Release and Apoptosis
Next, we determined the requirement of Nur77 interac-Interaction with Bcl-2 Mediates Nur77
tion with Bcl-2 for Nur77-induced cyt c release and apo-Mitochondrial Targeting
ptosis. Transient expression of Nur77/DBD or Bcl-2To determine whether interaction with Bcl-2 mediated
alone did not cause release of cyt c from mitochondriaNur77 mitochondrial targeting, we transfected GFP-
in HEK293T cells, as confocal microscopy analysisNur77/DBD alone or with Bcl-2 into HEK293T cells,
showed punctate cyt c staining, indicative of mitochon-which lack detectable levels of endogenous Bcl-2. GFP-
drial cyt c (Figure 5A). However, their coexpression re-Nur77/DBD was diffusely distributed in the cytosol
sulted in their colocalization and release of cyt c from(Figure 4A), indicating that it failed to target mitochon-
mitochondria (Figure 5A). Cyt c release required mito-dria. However, when coexpressed with Bcl-2, GFP-
chondrial localization of Nur77/DBD and Bcl-2, be-Nur77/DBD displayed a distribution pattern overlap-
cause it did not occur upon coexpression of Nur77/ping with mitochondrial Hsp60. Thus, Bcl-2 expression
DBD with Bcl-2/TM, a Bcl-2 mutant unable to targetconferred mitochondrial targeting to Nur77/DBD. The
mitochondria (Figure 5A). Interestingly, coexpression ofcolocalization of Nur77/DBD and Hsp60 was depen-
Nur77/DBD and Bcl-2/Y108K did not induce cyt c re-dent on Nur77/DBD binding to Bcl-2, because mutants
lease, although they colocalized (Figure 5A). These re-of GFP-Nur77/DBD (Nur77/DBD/L487A and Nur77/
sults suggest that the interaction between Nur77/DBDDBD/471–488) that failed to bind Bcl-2 (Figure 2) did
and Bcl-2 is insufficient for inducing cyt c release.not colocalize with mitochondria.
Expression of either Nur77/DBD or Bcl-2 alone didThe role of Bcl-2 in mitochondrial targeting of Nur77
not induce apoptosis, as revealed by the absence ofwas further studied by examining the accumulation of
nuclear fragmentation and chromatin condensation inBcl-2 binding Nur77/DBD and nonbinding Nur77/
HEK293T cells (Figure 5B). However, when coex-DBD/471–488 in mitochondria-enriched heavy mem-
pressed, Bcl-2 and Nur77/DBD induced striking apo-brane (HM) fractions of HEK293T cells (Figure 4B). HM
ptosis. The proapoptotic effect of Bcl-2 was specific topreparation purity was established by assessing levels
Nur77, because Bax-induced apoptosis was effectivelyof mitochondrial Hsp60, nuclear protein PARP, and cyto-
prevented by Bcl-2 coexpression (see below). Thus,solic/nuclear protein Jun N-terminal kinase (JNK).
Bcl-2 promotes apoptosis when coexpressed withNur77/DBD accumulated in the HM fraction when Bcl-2
Nur77 but suppresses apoptosis when coexpressedwas coexpressed, whereas Nur77/DBD/471-488 did
with Bax.not accumulate irrespective of Bcl-2 coexpression.
We next examined the role of endogenous Bcl-2 onTo complement these gene transfection experiments,
Nur77-dependent apoptosis in MGC80-3 cells. Treat-small interfering (si)RNA was used to determine whether
ment of control GFP-siRNA-transfected cells with 3-Cl-
suppressing endogenous Bcl-2 expression affected
AHPC resulted in apoptosis (Figures 5C and 5D).
Nur77 mitochondrial targeting. In MGC80-3 gastric can-
However, transfection of Bcl-2 siRNA suppressed 3-Cl-
cer cells, in which Nur77 was reported to target mito- AHPC-induced apoptosis by about 60%. Similar results
chondria in response to specific apoptotic stimuli (Liu were obtained in H460 cells (Supplemental Figure S1
et al., 2002), Bcl-2 expression was almost completely available on Cell website). Moreover, expression of
inhibited by Bcl-2-specific siRNA but not by GFP siRNA Bcl-2/1-90 protein also suppressed Nur77-dependent
control (Figure 4C). Both confocal microscopy (Figure apoptosis induced by TPA and 3-Cl-AHPC in LNCaP
4D) and immunoblotting of HM fractions (Figure 4E) re- cells (Figure 5E). Thus, Bcl-2 can manifest a proapo-
vealed that endogenous Nur77 targeted mitochondria in ptotic phenotype in settings where Nur77 is expressed
MGC80-3 cells treated with 3-Cl-AHPC. However, Bcl-2 and targets to mitochondria.
siRNA, but not control GFP siRNA, largely abolished To extend the above findings to primary cells, we
mitochondrial targeting of Nur77. Similarly, inhibition of performed experiments using primary cultures of pe-
endogenous Bcl-2 expression using Bcl-2 antisense oli- ripheral blood lymphocytes (PBLs). Freshly isolated
gonucleotides impaired Nur77 mitochondrial targeting PBLs were transfected with GFP-Nur77, then treated
in H460 lung cancer cells (Supplemental Figure S1 avail- with TPA plus calcium ionophore ionomycin, which in-
able at http://www.cell.com/cgi/content/full/116/4/ duce Nur77-dependent apoptosis of T-lymphocytes
527/DC1). (Woronicz et al., 1994). The treatment caused transloca-
We next studied whether the Bcl-2 loop region could tion of GFP-Nur77 from the nucleus to the cytoplasm,
act in a dominant-negative fashion to inhibit Nur77 mito- colocalizing with cotransfected DsRed2-Mito, a red fluo-
chondrial targeting. In LNCaP cells transfected with rescent protein (RFP) fused with a mitochondria-tar-
GFP-Bcl-2/1-90, a Bcl-2 mutant comprised of the first geting sequence (Figure 6A). Subcellular fractionation
90 N-terminal amino acids, TPA-induced Nur77 failed revealed that the treatment induced accumulation of
to target mitochondria, displaying a diffuse cytosolic endogenous Nur77 in HM fractions (Figure 6B). Interest-
distribution pattern, in contrast to nontransfected cells, ingly, this treatment also altered the migration of Nur77
which exhibited colocalization of Nur77 and Hsp60 (Fig- protein, suggesting a possible posttranslational modifi-
ure 4F). Thus, Bcl-2/1-90 inhibits Nur77 mitochondrial cation. Thus, both transfected and endogenous Nur77
targets mitochondria in primary lymphocytes.targeting, probably by competing with endogenous
Cell
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Figure 4. Nur77/Bcl-2 Interaction Mediates Nur77 Mitochondrial Localization
(A) Bcl-2 expression promotes Nur77/DBD mitochondrial localization. The indicated GFP-Nur77 mutant (3 g) and Bcl-2 (1 g) were expressed
in HEK293T cells alone or together. Cells were immunostained with anti-Bcl-2 or anti-Hsp60 antibody. Bcl-2, Nur77/DBD, its mutants, and
mitochondria (Hsp60) were visualized using confocal microscopy and the images were overlaid (overlay). Approximately 30% of cells showed
Nur77/DBD colocalization with Bcl-2 and Hsp60, while less than 5% of cells transfected with Nur77/DBD mutants were similarly colocalized.
In the absence of Bcl-2, Nur77/DBD did not colocalize with Hsp60.
(B) Immunoblotting analysis of the effect of Bcl-2 expression. GFP-Nur77/DBD or GFP-Nur77/DBD/471-488 (6 g) and Bcl-2 (2 g) were
transfected into HEK293T cells alone or together. HM fractions were prepared and analyzed for accumulation of Nur77/DBD in mitochondria
by immunoblotting using anti-GFP antibody. The same membrane was also blotted with anti-Bcl-2, anti-Hsp60, anti-PARP, or anti-JNK
antibody. Whole lysate was prepared from cells transfected with Nur77/DBD and Bcl-2.
(C) Inhibition of Bcl-2 expression by Bcl-2 siRNA. MGC80-3 cells were transfected with Bcl-2 siRNA SMARTpool or control GFP siRNA or left
alone. After 48 hr, lysates were prepared and assayed by immunoblotting using anti-Bcl-2 and anti--actin antibodies.
(D–E) Inhibition of endogenous Bcl-2 expression abrogates 3-Cl-AHPC-induced Nur77 mitochondrial targeting. MGC80-3 cells transfected
with siRNA as described in (C) were treated with 3-Cl-AHPC (106 M) for 5 hr. Cells were immunostained with anti-Nur77 and anti-Hsp60
antibodies for confocal microscopy analysis (D) or subjected to HM fractionation and analysis (E) as described in (B).
(F) Bcl-2/1-90 inhibits Nur77 mitochondrial targeting. LNCaP cells were transfected with GFP-Bcl-2/1-90 (4 g). After 24 hr, cells were treated
with TPA (100 ng/ml) for 3 hr and immunostained with anti-Nur77 and anti-Hsp60 antibodies, followed by confocal microscopy analysis.
Approximately 77% of transfected cells showed the effect presented.
We also studied the role of Bcl-2 in Nur77-dependent siRNA (Figure 6C). In addition, GFP-Nur77/DBD also
colocalized extensively with DsRed2-Mito (Figure 6D)apoptosis in PBLs. Treatment with TPA/ionomycin in-
duced extensive apoptosis of PBLs, which was partially and potently induced PBL apoptosis (Figure 6E), which
was almost completely suppressed by Bcl-2 antisenseinhibited by Bcl-2 antisense oligonucleotides or Nur77
Bcl-2 Conversion by Nur77/TR3
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Figure 5. Interaction of Nur77 with Bcl-2 Results in cyt c Release and Apoptosis
(A) Induction of cyt c release by coexpression of Bcl-2 and Nur77/DBD. GFP-Nur77/DBD (6 g) and Bcl-2 (2 g) were expressed in HEK293T
cells alone and together. GFP-Nur77/DBD was also coexpressed with Bcl-2/TM or Bcl-2/Y108K (2 g). Cells were immunostained with
anti-Bcl-2 or anti-cyt c antibody. Nur77/DBD, Bcl-2 and cyt c were visualized using confocal microscopy, and images for Nur77/DBD and
Bcl-2 were overlaid (overlay). Approximately 75% of the Nur77/DBD and Bcl-2 colocalized cells displayed various levels of diffuse cyt c staining.
(B) Induction of apoptosis by coexpression of Bcl-2 and Nur77/DBD. Bcl-2 and GFP-Nur77/DBD were expressed alone or together in
HEK293T cells. After 36 hr, cells were stained by anti-Bcl-2 antibody, followed by TRITC-conjugated secondary antibody (Sigma) and the
nucleus was stained by DAPI. Expression of Bcl-2 and GFP-Nur77/DBD, as well as nuclear morphology, were visualized by fluorescence
microscopy, and the three images were overlaid. Arrows indicate cells expressing Bcl-2 and GFP-Nur77/DBD. One of four similar experiments
is shown.
(C–D) Inhibition of endogenous Bcl-2 expression suppresses 3-Cl-AHPC-induced apoptosis. MGC80-3 cells were transfected with Bcl-2 siRNA
SMARTpool or control GFP siRNA. After 36 hr, cells were treated with 3-Cl-AHPC (106 M) for 48 hr. Apoptosis was determined by DAPI
staining as shown in (C) and scored by examining 300 cells for nuclear fragmentation and/or chromatin condensation (D).
(E) Bcl-2/1-90 inhibits TPA and 3-Cl-AHPC-induced apoptosis. LNCaP cells were transfected with GFP or GFP-Bcl-2/1-90. After 24 hr, cells
were treated with TPA (100 ng/ml) or 3-Cl-AHPC (106 M) for 24 hr. Apoptosis was studied as in D.
Cell
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Figure 6. Nur77 Mitochondrial Targeting in Human PBLs and Apoptotic Effects of Nur77 and Bcl-2 Mutants
(A) Mitochondrial targeting of Nur77 in PBLs. GFP-Nur77 (1 g) and pDsRed2-Mito (1 g) were transfected into freshly isolated human PBLs.
The cells were then treated with TPA (10 ng/ml) and ionomycin (0.5 M) for 30 min after 10 hr of transfection. GFP-Nur77 and mitochondria
(pDsRed2-Mito) were visualized using confocal microscopy. Approximately 20% of the cells showed the pattern presented.
(B) Endogenous Nur77 accumulates in the PBL HM fraction. PBLs were treated with TPA and ionomycin as in (A) for the indicated times and
HM fractions were isolated. Total cell lysates and HM fractions were subjected to immunoblotting as described in Figure 4B.
(C) Nur77 and Bcl-2 are required for apoptosis in PBLs. PBLs were transfected with control GFP siRNA, Nur77 siRNA, or Bcl-2 antisense
oligonucleotides (2 g). After 40 hr, cells were treated with TPA and ionomycin for 7 hr and apoptotic cells (Annexin-V positive) were determined
by flow cytometry. Bars represent average  means from two experiments.
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oligonucleotides (Figure 6F). Thus, endogenous Bcl-2 Bcl-2 Undergoes a Conformational Change
upon Nur77 Bindingcontributes to Nur77-dependent apoptosis in primary
Bax and Bak undergo conformational changes in associ-lymphocytes.
ation with their conversion from latent to active killer
proteins (Griffiths et al., 1999; Nechushtan et al., 1999).Analysis of Bcl-2 Domain Required for Apoptosis
We therefore explored whether a conformational changeInduction by Nur77
might be involved in converting Bcl-2 function from anti-
To characterize the proapoptotic mechanism of Bcl-2
apoptotic to proapoptotic. To this end, we compared
in Nur77-induced apoptosis, various Nur77 and Bcl-2
the effects of Nur77 on binding of Bcl-2 to various anti-
mutants were coexpressed in HEK293T cells. Similar to
Bcl-2 antibodies that recognize different epitopes. Anti-
Nur77/DBD, coexpression of either DC3 or DC1 with
body binding to Bcl-2 was measured by immunofluores-
Bcl-2 strongly induced apoptosis (Figure 6G). Thus, the cence using flow cytometry or by immunoprecipitation.
minimal C-terminal domain of Nur77, capable of binding First, Bcl-2 was coexpressed with GFP-Nur77/DBD
Bcl-2, was sufficient to induce apoptosis when coex- or the control GFP in HEK293T cells, and immunostain-
pressed with Bcl-2. The requirement of Nur77 interaction ing was performed on fixed and permeabilized cells us-
with Bcl-2 for apoptosis was further illustrated by the ing rabbit polyclonal antibody against the whole Bcl-2
failure of Nur77 mutants (Nur77/DBD/DC1, Nur77/ protein (Bcl-2), mouse monoclonal antibody against
DBD/471-488, and Nur77/DBD/L487A) that failed to the Bcl-2 BH3 binding pocket (Bcl-2/BH3-pocket), or
bind Bcl-2 (Figure 2) to induce apoptosis when coex- polyclonal antibody against the Bcl-2 BH3 domain
pressed with Bcl-2 (Figure 6G). (Bcl-2/BH3-domain) (Figure 7A). Bcl-2 immunofluores-
Bcl-2 effectively suppressed apoptosis induced by cence was undetectable in control GFP-coexpressing
Bax expression in HEK293T cells (Figure 6H). Bcl-2 mu- cells stained with the Bcl-2/BH3-domain antibody but
tations (Y108K, L137A, G145A) that impaired its interac- dramatically increased in GFP-Nur77/DBD-coexpress-
tion with Bax (Figure 3B) abolished its inhibitory effect ing cells, suggesting increased availability of the BH3-
on Bax-induced apoptosis (Figure 6H), consistent with domain epitope upon Nur77/DBD coexpression (Fig-
previous observations that the Bcl-2 hydrophobic cleft ure 7A). In contrast, immunofluorescence obtained by
is essential for its antiapoptotic effect. staining with the Bcl-2/BH3-pocket antibody was re-
We then performed experiments to delineate the duced by coexpression of GFP-Nur77/DBD, suggest-
structure-function relationships for the proapoptotic ef- ing decreased availability of this epitope. Alterations in
fect of Bcl-2 in Nur77-induced apoptosis (Figure 6I). binding of epitope-specific antibodies to Bcl-2 in re-
Coexpression of Nur77/DBD with Bcl-2/Loop did not sponse to GFP-Nur77/DBD coexpression were not due
induce cell death, consistent with the inability of this to changes in Bcl-2 levels, because GFP-Nur77/DBD
Bcl-2 mutant to bind Nur77 (Figure 3). Though capable coexpression did not alter Bcl-2 immunofluorescence
of binding Nur77/DBD, mutants of Bcl-2 lacking the when stained with Bcl-2 antibody. In addition, both
membrane-anchoring TM domain, the BH1 domain, BH2 immunoblotting analysis (Figure 7A) and BD cytometric
domain, or BH3 domain were incapable of inducing apo- bead assays (Supplemental Figure S2 available on Cell
ptosis when coexpressed with Nur77/DBD. Similarly, website) revealed equivalent Bcl-2 levels with GFP or
although binding Nur77, a BH3 domain mutant of Bcl-2 GFP-Nur77/DBD coexpression. Nur77/DBD coexpres-
(Y108K) also failed to induce apoptosis when coex- sion also did not modify binding of these epitope-specific
pressed with Nur77/DBD. Moreover, mutations of the antibodies to Bcl-2/Loop (Supplemental Figure S3 avail-
BH3 binding pocket of Bcl-2, L137A, and G145A, which able on Cell website). The Nur77/DBD-induced change
abrogated the ability of Bcl-2 to suppress Bax-induced in Bcl-2 conformation was also observed in PBLs (Figure
apoptosis (Figure 6H), retained the ability to promote 7B and Supplemental Figure S4 available on Cell
apoptosis when coexpressed with Nur77/DBD. Thus, website).
an intact hydrophobic groove in Bcl-2 is required for Second, the effects of Nur77/DBD on Bcl-2 confor-
its antiapoptotic activity but not for its proapoptotic mation were studied using immunoprecipitation assays.
activity, demonstrating a structural distinction between These experiments showed that coexpression of Nur77/
DBD reduced binding of Bcl-2 to the Bcl-2/BH3-these two opposing phenotypes of Bcl-2.
(D) Nur77/DBD targets mitochondria in PBLs. pDsRed2-Mito and GFP or GFP-Nur77/DBD (1 g each) were cotransfected into PBLs. GFP-
Nur77/DBD and pDsRed2-Mito were visualized as described in (A). Approximately 30% of the transfected cells showed the pattern presented.
(E) Nur77/DBD induces apoptosis of PBLs. GFP or GFP-Nur77/DBD (2 g) was transfected into PBLs for 18 hr. The transfected (GFP-
positive) cell subpopulation was identified by flow cytometry (Kolluri et al., 1999). The apoptotic cells in the transfected (green histogram) and
nontransfected (purple histogram) cells were identified by Annexin-V-PE staining. The numbers represent % of transfected cells showing
Annexin-V staining compared to nontransfected cells from the same culture dish.
(F) Bcl-2 is required for Nur77/DBD-induced apoptosis. GFP-Nur77/DBD (1 g) was cotransfected into PBLs with control oligonucleotides
or Bcl-2 antisense oligonucleotides (2 g). After 48 hr, apoptotic cells were determined as described for (E). Bars represent average  means
from two measurements.
(G) Interaction of Nur77 with Bcl-2 is required for apoptotic effect of Nur77/Bcl-2 coexpression. The indicated Nur77 mutant (6 g) was
transfected with empty or Bcl-2 expression vector (2 g) into HEK293T cells. After 36 hr, apoptotic cells were determined by DAPI staining.
(H) Effect of Bcl-2 mutations on the apoptotic effect of Bax. HEK293T cells were transfected with the indicated expression vectors and
apoptotic cells were determined by DAPI staining.
(I) Effect of Bcl-2 mutations on the apoptotic effect of Nur77/Bcl-2 coexpression. Bcl-2 or a mutant was transfected with GFP or GFP-Nur77/
DBD into HEK293T cells. Apoptosis wan then determined by DAPI staining. Bars in (G)–(I) are meansSD from three independent experiments.
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Figure 7. Interaction of Nur77 with Bcl-2 Induces Bcl-2 Conformational Change
(A) Nur77 induces change in Bcl-2 conformation. Bcl-2 (5 g) was cotransfected into HEK293T cells with GFP or GFP-Nur77/DBD (5 g) for
14 hr. Portion of the transfected cells were subjected to immunoblotting to confirm similar expression of Bcl-2 in the two samples (right). The
remaining cells were divided into three different pools, which were immunostained with three different anti-Bcl-2 antibodies: Bcl-2, Bcl-2/
BH3-pocket (BD Transduction Labs), and Bcl-2/BH3 domain (Abgent), followed by SRPD-conjugated secondary antibody (Southern Biotech).
Transfected (GFP-positive) cells were identified by flow cytometry. Bcl-2 fluorescence from the transfected cells (green histogram) was
compared to that from the nontransfected cells (purple histogram). Similarly fluorescing cells were gated to compare Bcl-2 immunofluorescence
after GFP or GFP-Nur77/DBD coexpression. Numbers represent % of transfected cells showing Bcl-2 immunofluorescence compared to
the autofluorescence of the nontransfected cells from the same transfection.
(B) Change of Bcl-2 conformation by Nur77/DBD in PBLs. Bcl-2 (1 g) was cotransfected into PBLs with GFP or GFP-Nur77/DBD (1 g).
A portion of the cells were subjected to immunoblotting (Supplemental Figure S4 available on Cell website). The remaining cells were
immunostained with Bcl-2/BH3-domain antibody 10 hr after transfection as described in (A).
(C) Nur77/DBD modulates immunoprecipitation of Bcl-2 by epitope-specific anti-Bcl-2 antibodies. HEK293T cells were transfected with the
indicated expression vector. After 18 hr, cells lysates were prepared and incubated with the indicated anti-Bcl-2 antibody for immunoprecipita-
tion. Immunoprecipitates were subjected to immunoblotting using anti-Bcl-2 antibody (Santa Cruz).
(D) Alteration of Bcl-2 interaction with Bcl-XL by Nur77/DBD. The indicated Bcl-2 mutant and Bcl-XL were coexpressed with or without GFP-
Nur77/DBD in HEK293T cells. Lysates were immunoprecipitated by anti-Bcl-2 antibody, and immunoprecipitates examined by immunoblotting
using anti-Myc or anti-Bcl-2 antibody.
(E) Alteration of Bcl-2 interaction with Bak by Nur77/DBD. The indicated Bcl-2 mutant and Bak were coexpressed with or without GFP-
Bcl-2 Conversion by Nur77/TR3
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pocket antibody, but enhanced binding of Bcl-2 to the apoptosis (Figures 7I–7J). Thus, Bcl-2-mediated apo-
ptosis induced by Nur77 depends on multidomain pro-Bcl-2/BH3-domain antibody. In contrast, Nur77/DBD
did not affect the immunoprecipitation efficiency of the apoptotic Bcl-2-family proteins such as Bak.
Bcl-2 antibody (Figure 7C). Together, these results
demonstrate that Nur77 binding induces a Bcl-2 confor- Discussion
mational change that exposes its BH3 domain.
Proapoptotic BH3-only members of the Bcl-2 family Despite lacking classical mitochondria-targeting se-
quences, Nur77 translocates from the nucleus to mito-induce apoptosis by binding to other Bcl-2 family mem-
bers through their BH3 domains (Huang and Strasser, chondria, in response to specific cell death stimuli, to
trigger cyt c release and apoptosis. The results pre-2000; Kelekar and Thompson, 1998). We therefore ex-
amined whether Nur77 binding alters the ability of Bcl-2 sented here provide evidence that Nur77 targets mito-
chondria through its interaction with Bcl-2, revealing ato bind Bcl-XL or Bak (Figures 7D-7E). At least when
assessed in detergent containing cell lysates by Co-IP, crosstalk between Nur77 nuclear receptor and the Bcl-2
signalings. Furthermore, our results demonstrate thatBcl-2 bound Bcl-XL and Bak independently of Nur77
(data not shown). To address whether Bcl-2 bound dif- the interaction provokes a proapoptotic phenotype of
Bcl-2 by inducing a conformational change in Bcl-2 thatferently to Bcl-XL and Bak in the presence of Nur77/
DBD, two Bcl-2 mutants were analyzed. Bcl-2/L137A, results in exposure of its BH3 domain. Given that Bcl-2
has been shown to have proapoptotic phenotypes in aa BH3 binding pocket mutant that retained killing activity
in the presence of Nur77/DBD, interacted with Bcl-XL variety of contexts, it will be interesting to explore in the
future whether Nur77 serves as the mediator of thisand Bak only when Nur77/DBD was coexpressed. In
contrast, binding of Bcl-XL and Bak to the Bcl-2/Y108K phenotypic conversion versus other Bcl-2 binding pro-
teins that may await discovery.BH3 domain mutant was unaffected by coexpression of
Nur77 (Figures 7D and 7E). Thus, Nur77 binding may Our mutagenesis studies indicate that the loop region
located between the BH4 and BH3 domains of Bcl-2 isresult in altered association of Bcl-2 with other Bcl-2
family members. Moreover, the observation that Bcl-2/ required for Nur77 binding. Previous studies (Chang et
al., 1997) demonstrated that the loop regions of Bcl-2L137A, but not Bcl-2/Y108K, was capable of killing cells
in collaboration with Nur77/DBD (Figure 6I) suggests and Bcl-XL act as an autoinhibitory domain that reduces
the antiapoptotic function of Bcl-2 and Bcl-XL. Our datathat exposure of the BH3 domain of Bcl-2 may be re-
sponsible for the conversion of Bcl-2 to a proapo- suggest that this conserved loop segment found in the
vertebrate orthologs of Bcl-2 and Bcl-XL may also partic-ptotic molecule.
The above data suggest that Bcl-2, upon Nur77 bind- ipate in converting the phenotype of Bcl-2 from a protec-
tor to a killer of cells. Intriguingly, deletion of the looping, induces apoptosis through its BH3 domain. BH3-
only proteins exert their apoptotic effects through either region of Bcl-2 blocks paclitaxel-induced apoptosis (Sri-
vastava et al., 1999), thereby suggesting the requirementBax or Bak. We therefore examined the involvement of
Bax and Bak in Bcl-2-dependent apoptosis induced by of the loop region for the apoptotic effect of certain
anticancer drugs. Though controversial, paclitaxel mayNur77. Coexpression of Nur77/DBD and Bcl-2 resulted
in a similar degree of apoptosis in HCT116 cells and also bind directly to the Bcl-2 loop domain to exert its
apoptotic effect (Rodi et al., 1999). For Bcl-XL, deamida-HCT116 cells lacking Bax (HCT116 Bax/) (Figure 7F),
suggesting that expression of Bax is not crucial. This tion of residues in its loop region is associated with
down regulation of its antiapoptotic activity (Devermanwas also supported by the observation that H460 cells,
which underwent extensive apoptosis in response to et al., 2002). In another study, insulin receptor substrate
(IRS) protein binds to the Bcl-2 loop region, enhancing3-Cl-AHPC (Supplemental Figure S1 available on Cell
website), expressed only trace levels of Bax (Figure 7G). rather than inhibiting its antiapoptotic function (Ueno
et al., 2000). It would be interesting therefore to studyTo determine whether Bak, which was highly ex-
pressed in H460 cells (Figure 7G), plays a role in Bcl-2- whether Nur77 and IRS compete for binding to Bcl-2,
exhibiting opposing effects on apoptosis.dependent apoptosis induced by Nur77, we examined
the effects of suppressing endogenous Bak expression. The Bcl-2 family members can be divided into two
functional subgroups based on whether the BH3 domainSignificant reductions of Bak protein were observed
when H460 cells were transfected with Bak siRNA but is available (Gross et al., 1999). Members with buried
BH3 domains are antiapoptotic, while members havingnot control siRNA (Figure 7H), correlating with significant
repression of Nur77-dependent 3-Cl-AHPC-induced an exposed BH3 domain are proapoptotic. Our analysis
Nur77/DBD in HEK293T cells. Lysates were immunoprecipitated by anti-Bcl-2 antibody, and immunoprecipitates examined by immunoblotting
using anti-Myc or anti-Bcl-2 antibody.
(F) Absence of Bax does not impair the apoptotic effect of Nur77/DBD. Nur77/DBD and Bcl-2 alone and together were transfected into
HCT116 cells (/) and HCT116 cells lacking Bax (/). After 36 hr, apoptotic cells were determined as in Figure 5D.
(G) Expression of Bax and Bak in cancer cell lines. Cell extracts prepared from the indicated cancer cell lines were analyzed for Bax and Bak
expression by immunoblotting.
(H) Inhibition of Bak expression by Bak siRNA in H460 lung cancer cells. H460 cells were transfected with Bak siRNA or control GFP siRNA.
After 48 hr, cell lysates were assayed by immunoblotting using anti-Bak antibody.
(I and J) Inhibition of endogenous Bak expression suppresses 3-Cl-AHPC-induced apoptosis. H460 cells were transfected with Bak siRNA or
control GFP siRNA. After 36 hr, cells were treated with 3-Cl-AHPC (106 M) for 24 hr. Apoptosis was determined by DAPI staining (I) and
scored (J) as in Figures 5C and 5D.
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using epitope-specific anti-Bcl-2 antibodies revealed been seen during clinical progression of lymphomas
that Bcl-2 undergoes a conformational change upon (Tanaka et al., 1992), suggesting the possibility of es-
Nur77 binding. Given that Nur77/DBD binding reduced cape from the conversion mechanism in some types of
epitope availability for an anti-Bcl-2 antibody to the BH3 cancer. Importantly, the discovery of a mechanism for
binding pocket and enhanced the epitope availability converting Bcl-2 from a protector to a killer might be
for an antibody to the BH3-domain (Figures 7A–7C), it exploited eventually for developing anticancer drugs
is likely that Nur77 binding induces a rearrangement of that turn overexpression of endogenous Bcl-2, which
the Bcl-2 hydrophobic crevice, resulting in exposure of occurs in approximately half of all human malignancies,
the otherwise hidden BH3 domain. Such a notion is into an advantage that promotes tumor cell apoptosis.
supported by our findings that the Bcl-2/L137A mutant
Experimental Proceduresexhibited enhanced binding to Bak or Bcl-XL upon
Nur77/DBD coexpression, while the Bcl-2 BH3 domain
(See Supplemental Data available on Cell website for detailed proce-mutant (Bcl-2/Y108K) failed to show such a response
dures)
(Figures 7D–7E). Based on the observation that Bcl-2
can associate with Bak in Nur77-overexpressing cells, Bcl-2 siRNAs and Antisense Oligonucleotides
we speculate that Nur77-converted Bcl-2 may similarly The target siRNA SMARTpools for Bcl-2 and Bak and the siRNA
function as an agonist of Bak, in addition to an antago- oligonucleotide for Nur77 (5-CAG UCC AGC CAU GCU CCU dTdT)
were purchased from Dharmacon Research Inc. They were trans-nist of Bcl-XL. Future mutagenesis studies will help to
fected into cells according to the manufacturer’s recommendations.determine whether this hypothesis is correct. However,
Bcl-2 antisense oligonucleotide targeting Bcl-2 and negative controlit is noteworthy that of the 15 known BH3-only proteins
oligonucleotides were obtained from Calbiochem.in humans and mice, Bid and Bim are the only members
that are capable of binding and activating proapoptotic Nur77/Bcl-2 Interaction Assays
Bcl-2-family proteins Bax and Bak (Korsmeyer et al., Reporter gene and GST pull-down assays were described previously
2000; Marani et al., 2002), suggesting a possible role for (Li et al., 2000; Wu et al., 1997). For the mammalian two-hybrid
assays, pcDNA-Gal4TAD-Nur77, pcDNA-Gal4TAD-Nur77/DBD,Bcl-2 when converted to a BH3-displaying killer.
pcDNA-Gal4DBD-Bcl-2/TM, and pcDNA-Gal4DBD-RXR wereCaspase-mediated cleavage within the loop domain
cloned and used. For Co-IP assays, HEK293T cells were transientlyof Bcl-2 converts it into a proapoptotic molecule (Cheng
transfected with various expression plasmids in the presence ofet al., 1997; Grandgirard et al., 1998). However, we do
caspase inhibitors (zVAD-fmk) to prevent degradation of Nur77 pro-
not believe that the Nur77-mediated conversion of Bcl-2 tein due to apoptosis. Antibodies used are: monoclonal mouse anti-
from a protector to a killer involves cleavage of the GFP (Medical and Biological Laboratories), monoclonal mouse anti-
protein, because we observed no hints of Bcl-2 cleavage HA (Roche Molecular Biochemicals), monoclonal mouse anti-FLAG
(Sigma), monoclonal mouse anti-Myc (Santa Cruz), polyclonal rabbitin Nur77 overexpressing cells by immunoblotting, and
anti-Nur77 (Active Motif), or monoclonal mouse anti-Bcl-2 (Santabecause a mutant of Bcl-2, in which the caspase cleav-
Cruz).age site has been mutated (Asp34), remains functional
in collaborating with Nur77 to induce apoptosis although
Isolation and Transfection of Human Peripheral
with reduced activity (Supplemental Figure S5 available Blood Lymphocytes (PBLs)
on Cell website). Since caspase-mediated or experimen- PBLs were isolated from leukocyte-enriched buffy coats from San
tal removal of the BH4 domain converts Bcl-2 into a Diego Blood Bank by centrifuging on Ficoll-paque Plus (Amersham
Pharmacia Biotech). The mononuclear cells were cultured in RPMIkiller, it is conceivable that the BH4 domain of Bcl-2
containing 10% FBS and 20 mM HEPES. Freshly isolated cells (107functions as an inhibitory domain to prevent the expo-
cells) were transfected using the human T Cell Nucleofector solutionsure of the BH3 domain. Three-dimensional structure of
(Amaxa Biosystems) as per the procedure recommended by theBcl-2 reveals an extensive interaction between the BH4
manufacturer.
domain and the hydrophobic groove (Petros et al., 2001).
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